1. Home
  2. TOI vs SCLX Comparison

TOI vs SCLX Comparison

Compare TOI & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TOI
  • SCLX
  • Stock Information
  • Founded
  • TOI 2007
  • SCLX 2011
  • Country
  • TOI United States
  • SCLX United States
  • Employees
  • TOI N/A
  • SCLX N/A
  • Industry
  • TOI Medical/Nursing Services
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • TOI Health Care
  • SCLX Health Care
  • Exchange
  • TOI Nasdaq
  • SCLX Nasdaq
  • Market Cap
  • TOI 49.1M
  • SCLX 51.3M
  • IPO Year
  • TOI N/A
  • SCLX N/A
  • Fundamental
  • Price
  • TOI $1.14
  • SCLX $0.23
  • Analyst Decision
  • TOI
  • SCLX Strong Buy
  • Analyst Count
  • TOI 0
  • SCLX 4
  • Target Price
  • TOI N/A
  • SCLX $14.00
  • AVG Volume (30 Days)
  • TOI 558.9K
  • SCLX 1.1M
  • Earning Date
  • TOI 03-24-2025
  • SCLX 05-12-2025
  • Dividend Yield
  • TOI N/A
  • SCLX N/A
  • EPS Growth
  • TOI N/A
  • SCLX N/A
  • EPS
  • TOI N/A
  • SCLX N/A
  • Revenue
  • TOI $393,412,000.00
  • SCLX $55,152,000.00
  • Revenue This Year
  • TOI $23.95
  • SCLX $24.19
  • Revenue Next Year
  • TOI N/A
  • SCLX $109.90
  • P/E Ratio
  • TOI N/A
  • SCLX N/A
  • Revenue Growth
  • TOI 21.33
  • SCLX 22.02
  • 52 Week Low
  • TOI $0.13
  • SCLX $0.21
  • 52 Week High
  • TOI $1.63
  • SCLX $2.30
  • Technical
  • Relative Strength Index (RSI)
  • TOI 64.39
  • SCLX 30.70
  • Support Level
  • TOI $0.97
  • SCLX $0.22
  • Resistance Level
  • TOI $1.34
  • SCLX $0.34
  • Average True Range (ATR)
  • TOI 0.17
  • SCLX 0.03
  • MACD
  • TOI 0.04
  • SCLX -0.00
  • Stochastic Oscillator
  • TOI 63.83
  • SCLX 8.47

About TOI The Oncology Institute Inc.

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: